<html lang="en" class="pb-page js" data-request-id="94d62e2bb47e1d0f-GRU"><head data-pb-dropzone="head"><style type="text/css" nonce="94d62e2bb47e1d0f-GRU">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/vJMUuKA-kq49xisEzWAIlSFIMjO7oh5iFfzsnQbrW3KXyjkZxfCwo4NRuxUlmoXvuJRX4RqlwRmDxJVNndZuLg=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Olaparib for Metastatic Castration-Resistant Prostate Cancer | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d62e2bb47e1d0f-GRU">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.5177955442900948"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Urology/Prostate Disease General|Treatments in Oncology">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Urology/Prostate Disease|Hematology/Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1911440","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","category":"Research","type":"Original Article","topics":"Urology/Prostate Disease General|Treatments in Oncology","specialties":"Urology/Prostate Disease|Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-05-28T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Urology/Prostate Disease General|Treatments in Oncology\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Urology/Prostate Disease|Hematology/Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1911440","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Quick Take","title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","doi":"10.1056/NEJMdo005740","issueDate":"2020-05-28T00:00Z","age":"6Months-1990","isFree":"n","topics":"Urology/Prostate Disease General|Treatments in Oncology","viewType":"Full","specialties":"Urology/Prostate Disease|Hematology/Oncology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d62e2bb47e1d0f-GRU">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Olaparib for Metastatic Castration-Resistant Prostate Cancer"><meta name="dc.Creator" content="Johann de Bono"><meta name="dc.Creator" content="Joaquin Mateo"><meta name="dc.Creator" content="Karim Fizazi"><meta name="dc.Creator" content="Fred Saad"><meta name="dc.Creator" content="Neal Shore"><meta name="dc.Creator" content="Shahneen Sandhu"><meta name="dc.Creator" content="Kim N. Chi"><meta name="dc.Creator" content="Oliver Sartor"><meta name="dc.Creator" content="Neeraj Agarwal"><meta name="dc.Creator" content="David Olmos"><meta name="dc.Creator" content="Antoine Thiery-Vuillemin"><meta name="dc.Creator" content="Przemyslaw Twardowski"><meta name="dc.Creator" content="Niven Mehra"><meta name="dc.Creator" content="Carsten Goessl"><meta name="dc.Creator" content="Jinyu Kang"><meta name="dc.Creator" content="Joseph Burgents"><meta name="dc.Creator" content="Wenting Wu"><meta name="dc.Creator" content="Alexander Kohlmann"><meta name="dc.Creator" content="Carrie A. Adelman"><meta name="dc.Creator" content="Maha Hussain"><meta name="dc.Description" content="Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate–ribose) polymer..."><meta name="Description" content="Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate–ribose) polymer..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-05-28"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1911440"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202005283822208"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1911440">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1911440">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1911440">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM">
        <meta property="og:title" content="Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1911440">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/b3186816-8d37-4708-afa5-bb563ae2327c/nejmoa1911440_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/b3186816-8d37-4708-afa5-bb563ae2327c/nejmoa1911440_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Multiple loss-of-function alterations in genes that are involved in DNA repair, including
homologous recombination repair, are associated with response to poly(adenosine diphosphate–ribose)
polymer...">
        <meta name="twitter:description" content="Multiple loss-of-function alterations in genes that are involved in DNA repair, including
homologous recombination repair, are associated with response to poly(adenosine diphosphate–ribose)
polymer...">
    


    
    
        <meta property="og:image:width" content="2632">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1911440">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1911440">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa1911440;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2020.382.issue-22;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1911440" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1911440" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1911440" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1911440" class="inputDoi"><input type="hidden" value="J. de Bono and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;382:2091-2102" class="inputCitation"><input type="hidden" value="04-28-2020" class="inputEPubDate"><input type="hidden" value="May 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Olaparib for Metastatic Castration-Resistant Prostate Cancer" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d62e2bb47e1d0f-GRU"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Olaparib for Metastatic Castration-Resistant Prostate Cancer</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Johann</span> <span property="familyName">de Bono</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2034-595X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-2034-595X</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joaquin</span> <span property="familyName">Mateo</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Karim</span> <span property="familyName">Fizazi</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fred</span> <span property="familyName">Saad</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Neal</span> <span property="familyName">Shore</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shahneen</span> <span property="familyName">Sandhu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kim N.</span> <span property="familyName">Chi</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+12</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Oliver</span> <span property="familyName">Sartor</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-8777-7343" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-8777-7343</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Neeraj</span> <span property="familyName">Agarwal</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Olmos</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Antoine</span> <span property="familyName">Thiery-Vuillemin</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Przemyslaw</span> <span property="familyName">Twardowski</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Niven</span> <span property="familyName">Mehra</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carsten</span> <span property="familyName">Goessl</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jinyu</span> <span property="familyName">Kang</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joseph</span> <span property="familyName">Burgents</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wenting</span> <span property="familyName">Wu</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alexander</span> <span property="familyName">Kohlmann</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carrie A.</span> <span property="familyName">Adelman</span>, <span property="honorificSuffix">Ph.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Maha</span> <span property="familyName">Hussain</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-12</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">April 28, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">382</span></span>:<span property="pageStart">2091</span>-<span property="pageEnd">2102</span></div><div class="doi">DOI: 10.1056/NEJMoa1911440</div><div class="core-enumeration"><a href="/toc/nejm/382/22"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">382</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">22</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJohann%2Bde%2BBono%252C%2BJoaquin%2BMateo%252C%2BKarim%2BFizazi%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D22%26contentID%3D10.1056%252FNEJMoa1911440%26title%3DOlaparib%2Bfor%2BMetastatic%2BCastration-Resistant%2BProstate%2BCancer%26publicationDate%3D05%252F28%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1911440" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJohann%2Bde%2BBono%252C%2BJoaquin%2BMateo%252C%2BKarim%2BFizazi%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D22%26contentID%3D10.1056%252FNEJMoa1911440%26title%3DOlaparib%2Bfor%2BMetastatic%2BCastration-Resistant%2BProstate%2BCancer%26publicationDate%3D05%252F28%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/d5ce18a3-558f-4276-aec4-44715cc65595/nejmoa1911440.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1911440.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1911440" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1911440" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1911440.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition in patients with prostate and other cancers.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). All the men had a qualifying alteration in prespecified genes with a direct or indirect role in homologous recombination repair. Cohort A (245 patients) had at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i>; cohort B (142 patients) had alterations in any of 12 other prespecified genes, prospectively and centrally determined from tumor tissue. Patients were randomly assigned (in a 2:1 ratio) to receive olaparib or the physician’s choice of enzalutamide or abiraterone (control). The primary end point was imaging-based progression-free survival in cohort A according to blinded independent central review.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P&lt;0.001); a significant benefit was also observed with respect to the confirmed objective response rate and the time to pain progression. The median overall survival in cohort A was 18.5 months in the olaparib group and 15.1 months in the control group; 81% of the patients in the control group who had progression crossed over to receive olaparib. A significant benefit for olaparib was also seen for imaging-based progression-free survival in the overall population (cohorts A and B). Anemia and nausea were the main toxic effects in patients who received olaparib.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp &amp; Dohme; PROfound ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02987543" target="_blank">NCT02987543</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo005740/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/e04e4d27-50b2-4303-986e-56fa4262fe81/media/NEJMdo005740_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo005740/full/" class="ng-do-media_item-title-link">Olaparib for Metastatic Castration-Resistant Prostate Cancer</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 20s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Metastatic castration-resistant prostate cancer is a heterogeneous disease with poor outcomes.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4 r5 r6" id="body-ref-r6" href-manipulated="true">1-6</a></sup> Tumors in up to 30% of patients harbor deleterious aberrations in genes involved in repairing DNA damage.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3-2" href-manipulated="true">1-3</a></sup> Among the most common of these alterations, <i>BRCA1</i> and <i>BRCA2</i> are well-characterized genes involved in homologous recombination repair, and <i>ATM</i> functions as a DNA-damage checkpoint and indirectly activates homologous recombination repair.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8" href-manipulated="true">7,8</a></sup> Loss-of-function alterations in these and other genes with a direct or indirect role in homologous recombination repair are associated with more aggressive prostate cancers.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10 r11" id="body-ref-r11" href-manipulated="true">9-11</a></sup> Such gene alterations confer sensitivity to poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition in prostate and other cancers.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r13 r14 r15 r16 r17 r18 r19" id="body-ref-r19-1" href-manipulated="true">12-19</a></sup> The response to PARP inhibition may occur through multiple mechanisms, including PARP trapping, which is the physical obstruction of replication forks leading to DNA double-strand breaks and defects in homologous recombination repair.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup></div><div role="paragraph">The PROfound trial is a prospective, biomarker-selected, phase 3 trial involving men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). Patients with a qualifying alteration in prespecified genes with a direct or indirect role in homologous recombination repair were randomly assigned to receive the PARP inhibitor olaparib or the physician’s choice of either enzalutamide or abiraterone (control group). The primary objective was efficacy, as assessed by blinded independent central review of imaging-based progression-free survival in patients with alterations in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i>.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">Eligible patients were men (≥18 years of age) with confirmed metastatic castration-resistant prostate cancer whose disease had progressed during treatment with enzalutamide or abiraterone, administered for metastatic or nonmetastatic castration-resistant prostate cancer or for metastatic hormone-sensitive prostate cancer. Previous taxane chemotherapy was allowed. Men without previous surgical castration were required to continue luteinizing-hormone–releasing hormone analogue therapy. All the patients had adequate organ and bone marrow function. Full eligibility criteria are provided in the trial <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org. All the patients provided written informed consent.</div><div role="paragraph">An investigational clinical trial assay, based on the FoundationOne CDx next-generation sequencing test developed in partnership with Foundation Medicine, was used to prospectively identify patients with qualifying deleterious or suspected deleterious alterations in at least 1 of the 15 prespecified genes selected for their direct or indirect role in homologous recombination repair: <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>BRIP1</i>, <i>BARD1</i>, <i>CDK12</i>, <i>CHEK1</i>, <i>CHEK2</i>, <i>FANCL</i>, <i>PALB2</i>, <i>PPP2R2A</i>, <i>RAD51B</i>, <i>RAD51C</i>, <i>RAD51D</i>, and <i>RAD54L</i>. Tumor testing was conducted centrally with the use of archival or recent biopsy tissue from primary or metastatic disease. The presence of a deleterious or suspected deleterious alteration according to the central tumor test was required for eligibility, irrespective of the zygosity of the alteration. Additional details are provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org. Exploratory analyses of germline as compared with somatic origin and variant zygosity are being investigated and are not reported here.</div></section><section id="sec-1-2"><h3>Trial Design and Interventions</h3><div role="paragraph">This was a prospective, randomized, open-label, phase 3 trial. Eligible patients were included in one of two cohorts depending on their qualifying gene alteration. <a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> were assigned to cohort A, regardless of co-occurring qualifying alterations in any of the other genes. Patients with alterations in any of the other 12 genes were assigned to cohort B. The overall population comprised patients from cohort A and cohort B (i.e., patients with a qualifying alteration in any of the 15 prespecified genes).</span></div><div role="paragraph">A central interactive voice-response or Web-response system was used to randomly assign patients in a 2:1 ratio to receive the standard dose of olaparib tablets (300 mg twice daily) or the prespecified physician’s choice of enzalutamide (160 mg once daily) or abiraterone (1000 mg once daily, plus prednisone at a dose of 5 mg twice daily) (control group). Randomization was stratified according to previous taxane use (yes or no) and measurable disease (yes or no). Measurable disease was determined by investigators at baseline according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (longest diameter of soft-tissue lesions, ≥10 mm; short-axis diameter of lymph nodes, ≥15 mm). Treatment was continued until objective imaging-based disease progression, assessed by blinded central review by an independent third-party vendor, or until the occurrence of unacceptable toxic effects. Patients who were assigned to the control group were eligible to cross over to receive olaparib treatment after independent review–confirmed imaging-based progression (see the <a href="#ap2">Supplementary Appendix</a>).</div></section><section id="sec-1-3"><h3>End Points</h3><div role="paragraph">The primary end point was imaging-based progression-free survival, assessed by an independent review committee, in patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> (cohort A). Imaging-based progression-free survival was defined as the time from randomization until soft-tissue disease progression (by RECIST, version 1.1), bone lesion progression (by Prostate Cancer Clinical Trials Working Group 3 criteria), or death (see the <a href="#ap2">Supplementary Appendix</a>). A prespecified sensitivity analysis that was based on investigator assessment was performed. Imaging-based progression-free survival as assessed by independent review in the overall population was a key secondary end point.</div><div role="paragraph">Additional secondary end points included the confirmed objective response rate (defined as the percentage of patients who had an imaging-based complete response or partial response), the time to pain progression, overall survival (including a prespecified interim analysis, which is reported here), a reduction of at least 50% in the concentration of prostate-specific antigen (PSA) (PSA<sub>50</sub> response), and the circulating-tumor-cell conversion rate (defined as the percentage of patients with a decrease in the number of circulating tumor cells from ≥5 cells per 7.5 ml of whole blood at baseline to &lt;5 cells per 7.5 ml after baseline). The response rate was assessed among patients who could be evaluated and who had measurable disease at baseline as assessed by independent review according to RECIST, version 1.1. A prespecified sensitivity analysis for the crossover effect on overall survival was performed. Safety was assessed in the overall population through reporting of adverse events according to the Common Terminology Criteria Adverse Events, version 4.0, and collection of blood samples for clinical chemical and hematologic analyses. Assessments are described in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-4"><h3>Trial Oversight</h3><div role="paragraph">This trial was performed in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and the AstraZeneca and Merck policies on bioethics. The trial was designed by representatives of AstraZeneca in collaboration with the trial steering committee. AstraZeneca was responsible for overseeing the collection, analysis, and interpretation of the data. All the authors had full access to the data. Merck provided input regarding the interpretation of the data. The manuscript was written with medical writing assistance funded by AstraZeneca and Merck Sharp &amp; Dohme, with critical review and input by the authors. The authors attest to the accuracy and completeness of the data and the fidelity of the trial to the protocol.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">Efficacy data were analyzed on an intention-to-treat basis, and safety data were reported for all the patients who received at least one dose of a trial drug. With a sample size of approximately 240 patients in cohort A, 143 progression events or deaths (approximately 60% maturity) would provide the trial with 95% power, at a two-sided significance level of 5%, to show a significant difference in imaging-based progression-free survival between the olaparib group and the control group, under the assumption of a hazard ratio for progression or death of 0.53. For time-to-event end points, imaging-based progression-free survival, time to pain progression, and overall survival, P values were calculated with the use of stratified log-rank tests. Hazard ratios and 95% confidence intervals were calculated with the use of Cox proportional-hazards models, with stratification factors as covariates. The Kaplan–Meier method was used to calculate medians for each trial group. Logistic-regression models that were adjusted for stratification factors were used to analyze objective responses.</div><div role="paragraph">A multiple-testing procedure was used to control for the trial-wide type I error rate. If the primary end point in cohort A showed statistical significance, testing of key secondary end points was to be performed in a hierarchical manner: objective response rate (in cohort A), imaging-based progression-free survival (in the overall population), time to pain progression (in cohort A), and overall survival (in cohort A), according to the sequential calculation of a two-sided alpha level of 0.05 (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). For overall survival, the two-sided 5% level of alpha was split at the interim analysis (0.01) and final analysis (0.047) with the use of an O’Brien–Fleming spending function.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> Additional details are available in the <a href="#ap2">Supplementary Appendix</a>, and the statistical analysis plan is available with the protocol.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Screening and Randomization</h3><div role="paragraph">Overall, 4425 patients were enrolled for screening at 206 sites in 20 countries; 4047 patients had tumor tissue available for testing. Of these samples, 2792 (69%) were successfully sequenced with a biomarker status outcome reported. A qualifying alteration in 1 or more of the 15 prespecified genes with a direct or indirect role in homologous recombination repair was detected in 778 of 2792 patients (28%). Of these patients, 387 (50%) met all eligibility criteria and thus underwent randomization from April 2017 through November 2018. (For details on screening, randomization, and follow-up, see Fig. S2.)</div></section><section id="sec-2-2"><h3>Patient Characteristics</h3><div role="paragraph">In cohort A, 162 patients were randomly assigned to receive olaparib and 83 to the control treatment. In cohort B, 94 patients were randomly assigned to receive olaparib and 48 to the control treatment. The alteration status for the prespecified genes is summarized in Table S2. Although baseline characteristics appeared balanced overall between the olaparib group and the control group, the control group had a higher percentage of patients with visceral metastases and a higher median baseline PSA concentration, and the olaparib group had a higher percentage of patients with an <i>ATM</i> alteration (<a href="#t1">Table 1</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1911440_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1911440_t1.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/a216352e-de54-484c-a212-a2e6a4ff90d1/assets/images/large/nejmoa1911440_t1.jpg" height="2661" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Cohort A</span></th><th class="txxr-borders" colspan="2"><span>Cohorts A and B</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Olaparib<br>(N=162)</th><th class="xxxx-borders">Control<br>(N=83)</th><th class="xxxx-borders">Olaparib<br>(N=256)</th><th class="xxxr-borders">Control<br>(N=131)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age at randomization (range) — yr</td><td class="xxxx-borders shading">68 (47–86)</td><td class="xxxx-borders shading">67 (49–86)</td><td class="xxxx-borders shading">69 (47–91)</td><td class="xxxr-borders shading">69 (49–87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Age ≥65 yr at randomization — no. (%)</td><td class="xxxx-borders">108 (67)</td><td class="xxxx-borders">60 (72)</td><td class="xxxx-borders">174 (68)</td><td class="xxxr-borders">97 (74)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Metastatic disease at initial diagnosis — no. (%)</td><td class="xxxx-borders shading">38 (23)</td><td class="xxxx-borders shading">19 (23)</td><td class="xxxx-borders shading">66 (26)</td><td class="xxxr-borders shading">25 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Missing data</td><td class="xxxx-borders">7 (4)</td><td class="xxxx-borders">4 (5)</td><td class="xxxx-borders">11 (4)</td><td class="xxxr-borders">7 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Gleason score ≥8 — no./total no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">105/157 (67)</td><td class="xxxx-borders shading">54/80 (67)</td><td class="xxxx-borders shading">183/251 (73)</td><td class="xxxr-borders shading">95/127 (75)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Patients with alterations in a single gene — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>BRCA1</i></td><td class="xxxx-borders shading">8 (5)</td><td class="xxxx-borders shading">5 (6)</td><td class="xxxx-borders shading">8 (3)</td><td class="xxxr-borders shading">5 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>BRCA2</i></td><td class="xxxx-borders">80 (49)</td><td class="xxxx-borders">47 (57)</td><td class="xxxx-borders">81 (32)</td><td class="xxxr-borders">47 (36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>ATM</i></td><td class="xxxx-borders shading">60 (37)</td><td class="xxxx-borders shading">24 (29)</td><td class="xxxx-borders shading">62 (24)</td><td class="xxxr-borders shading">24 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>CDK12</i></td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">61 (24)</td><td class="xxxr-borders">28 (21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median PSA at baseline (IQR) — μg/liter</td><td class="xxxx-borders shading">62.2<br>(21.9–280.4)</td><td class="xxxx-borders shading">112.9<br>(34.3–317.1)</td><td class="xxxx-borders shading">68.2<br>(24.1–294.4)</td><td class="xxxr-borders shading">106.5<br>(37.2–326.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Measurable disease at baseline — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">95 (59)</td><td class="xxxx-borders">46 (55)</td><td class="xxxx-borders">149 (58)</td><td class="xxxr-borders">72 (55)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Metastases at baseline — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bone only</td><td class="xxxx-borders">57 (35)</td><td class="xxxx-borders">23 (28)</td><td class="xxxx-borders">86 (34)</td><td class="xxxr-borders">38 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Visceral: lung or liver</td><td class="xxxx-borders shading">46 (28)</td><td class="xxxx-borders shading">32 (39)</td><td class="xxxx-borders shading">68 (27)</td><td class="xxxr-borders shading">44 (34)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">49 (30)</td><td class="xxxx-borders">23 (28)</td><td class="xxxx-borders">88 (34)</td><td class="xxxr-borders">41 (31)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance status — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">84 (52)</td><td class="xxxx-borders">34 (41)</td><td class="xxxx-borders">131 (51)</td><td class="xxxr-borders">55 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">67 (41)</td><td class="xxxx-borders shading">46 (55)</td><td class="xxxx-borders shading">112 (44)</td><td class="xxxr-borders shading">71 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">11 (7)</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">13 (5)</td><td class="xxxr-borders">4 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Missing data</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Previous new hormonal agent — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Enzalutamide only</td><td class="xxxx-borders shading">68 (42)</td><td class="xxxx-borders shading">40 (48)</td><td class="xxxx-borders shading">105 (41)</td><td class="xxxr-borders shading">54 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Abiraterone only</td><td class="xxxx-borders">62 (38)</td><td class="xxxx-borders">29 (35)</td><td class="xxxx-borders">100 (39)</td><td class="xxxr-borders">54 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Enzalutamide and abiraterone</td><td class="xxxx-borders shading">32 (20)</td><td class="xxxx-borders shading">14 (17)</td><td class="xxxx-borders shading">51 (20)</td><td class="xxxr-borders shading">23 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Previous taxane use — no. (%)</td><td class="xxxx-borders">106 (65)</td><td class="xxxx-borders">52 (63)</td><td class="xxxx-borders">170 (66)</td><td class="xxxr-borders">84 (64)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Docetaxel only</td><td class="xxxx-borders shading">74 (46)</td><td class="xxxx-borders shading">32 (39)</td><td class="xxxx-borders shading">115 (45)</td><td class="xxxr-borders shading">58 (44)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cabazitaxel only</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Docetaxel and cabazitaxel</td><td class="xxxx-borders shading">29 (18)</td><td class="xxxx-borders shading">20 (24)</td><td class="xxxx-borders shading">51 (20)</td><td class="xxxr-borders shading">26 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Paclitaxel only</td><td class="xbxx-borders">1 (&lt;1)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (&lt;1)</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Cohort A included patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i>. Cohort B included patient with alterations in any of 12 other prespecified genes: <i>BRIP1</i>, <i>BARD1</i>, <i>CDK12</i>, <i>CHEK1</i>, <i>CHEK2</i>, <i>FANCL</i>, <i>PALB2</i>, <i>PPP2R2A</i>, <i>RAD51B</i>, <i>RAD51C</i>, <i>RAD51D</i>, and <i>RAD54L</i>. In both cohorts, patients in the control group received the physician’s choice of enzalutamide or abiraterone. ECOG denotes Eastern Cooperative Oncology Group, IQR interquartile range, NA not applicable, and PSA prostate-specific antigen.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">In general, scores on the Gleason scale range from 6 to 10, with higher scores indicating a worse prognosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">A total of 28 patients (21 in cohort A and 7 in cohort B) had mutations in more than one gene. A total of 4 patients were incorrectly assigned to cohort B (1 in the olaparib group had an alteration in <i>BRCA2</i>, 1 in the control group had alterations in <i>BRCA2</i> and <i>CDK12</i>, and 2 in the olaparib group had alterations in <i>ATM</i>).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Data were derived from electronic case-report forms as assessed by the investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">A total of 13 patients received a new hormonal agent for disease before a diagnosis of metastatic castration-resistant prostate cancer; all others received a new hormonal agent after the development of metastatic castration-resistant prostate cancer.</div></div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Efficacy</h3><section id="sec-2-3-1"><h4>Patients with at Least One Alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> (Cohort A)</h4><div role="paragraph">Analysis of the primary end point was performed after 174 of 245 patients in cohort A had had imaging-based progression by independent review or had died (data maturity, 71%; data cutoff date, June 4, 2019). <span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The median imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval [CI], 0.25 to 0.47; P&lt;0.001) (<a href="#f1">Figure 1A</a>).</span> A prespecified sensitivity analysis that was based on investigator assessment yielded similar results to the primary analysis (hazard ratio, 0.24; 95% CI, 0.17 to 0.34) (Table S4). Prespecified subgroup analyses are shown in <a href="#f2">Figure 2</a>.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f1.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/b3186816-8d37-4708-afa5-bb563ae2327c/assets/images/large/nejmoa1911440_f1.jpg" height="3438" width="2632" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Estimates of Imaging-Based Progression-free Survival and Interim Overall Survival.</div><div class="notes"><div role="doc-footnote">Panel A shows imaging-based progression-free survival, as assessed by blinded independent central review, in patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> (cohort A), who received either olaparib or the physician’s choice of enzalutamide or abiraterone (control group); Panel B shows interim overall survival in the same cohort. For patients with censored data in cohort A, the median duration of follow-up for imaging-based progression-free survival was 7.5 months in the olaparib group and 5.4 months in the control group; the median duration of follow-up for overall survival was 12.6 months and 13.2 months, respectively. Panel C shows imaging-based progression-free survival in cohorts A and B (overall population); patients in cohort B had alterations in any of 12 other prespecified genes. For patients with censored data in the overall population, the median duration of follow-up for imaging-based progression-free survival was 7.4 months in the olaparib group and 5.5 months in the control group. Overall, at the time of the analysis of imaging-based progression-free survival by blinded independent central review, 10 patients (4%) in the olaparib group and 8 (6%) in the control group had withdrawn consent, and their data were censored. (For interim overall survival in the overall population, see Fig. S3.)</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f2.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/840a7eee-0ab3-4666-9097-666025b6c990/assets/images/large/nejmoa1911440_f2.jpg" height="1671" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Prespecified Subgroup Analysis of Imaging-Based Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Shown is the subgroup analysis of patients in cohort A (Panel A) and those in the overall population (cohorts A and B) (Panel B). Subgroups in which fewer than five progression events or deaths occurred per group were not included in the analysis. The sizes of the circles are proportional to the number of events. The dashed line indicates the point of no effect (hazard ratio, 1.00). A hazard ratio of less than 1.00 favors olaparib. ECOG denotes Eastern Cooperative Oncology Group, and PSA prostate-specific antigen.</div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">The confirmed objective response rate among patients who could be evaluated was 33% (28 of 84 patients) in the olaparib group and 2% (1 of 43 patients) in the control group (odds ratio for an objective response, 20.86; 95% CI, 4.18 to 379.18; P&lt;0.001). The median time to pain progression was significantly longer in the olaparib group than in the control group (hazard ratio, 0.44; 95% CI, 0.22 to 0.91; P=0.02) (<a href="#f3">Figure 3A</a>).</span> A sensitivity analysis including death as an event in the absence of pain progression yielded similar results (Table S7). At this time, an interim analysis for overall survival was also conducted when 93 of 245 patients had died (data maturity, 38%) and yielded a median overall survival of 18.5 months with olaparib and 15.1 months with the control treatment (hazard ratio for death, 0.64; 95% CI, 0.43 to 0.97; P=0.02) (<a href="#f1">Figure 1B</a>). Among patients in the control group with independent review–confirmed imaging-based disease progression, 81% crossed over to receive olaparib treatment at the investigators’ discretion. The results of a sensitivity analysis for overall survival with adjustment for switching to olaparib treatment are shown in Table S8.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f3.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/5ff1be9a-2097-455a-83b5-e1e60cddd366/assets/images/large/nejmoa1911440_f3.jpg" height="2507" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Time to Pain Progression.</div><div class="notes"><div role="doc-footnote">Shown is the probability that patients had no progression of pain during treatment with olaparib or the control drug in cohort A (Panel A) and in cohorts A and B (Panel B). In this analysis, death was not considered as a competing risk. Time to pain progression was based on the worst-pain score (item 3) on the Brief Pain Inventory–Short Form and on opioid use.</div></div></figcaption></figure></div><div role="paragraph">Among patients who could be evaluated, 43% (66 of 153) in the olaparib group and 8% (6 of 77) in the control group had a PSA<sub>50</sub> response. Clearance of circulating tumor cells was observed in 30% (29 of 97) and 11% (5 of 44) of patients who could be evaluated in the olaparib and control groups, respectively.</div></section><section id="sec-2-3-2"><h4>Overall Population (Cohorts A and B)</h4><div role="paragraph"><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">In the overall population, the median imaging-based progression-free survival by independent review was significantly longer in the olaparib group than in the control group (5.8 months vs. 3.5 months; hazard ratio, 0.49; 95% CI, 0.38 to 0.63; P&lt;0.001) (<a href="#f1">Figure 1C</a>).</span> This finding was supported by sensitivity analysis by investigator assessment (Table S4). Exploratory findings with respect to imaging-based progression-free survival for individual genes are reported in <a href="#f2">Figure 2B</a>, with additional details in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">Among patients who could be evaluated, the confirmed objective response rate was 22% (30 of 138 patients) in the olaparib group and 4% (3 of 67 patients) in the control group (odds ratio, 5.93; 95% CI, 2.01 to 25.40). After 6 months, 85% of the patients in the olaparib group were free of pain progression, as compared with 75% in the control group (<a href="#f3">Figure 3B</a>). The median overall survival at interim analysis (data maturity, 41%) was 17.5 months in the olaparib group and 14.3 months in the control group (hazard ratio for death, 0.67; 95% CI, 0.49 to 0.93) (Fig. S3). Among patients in the control group with independent review–confirmed imaging-based progression, 82% crossed over to olaparib treatment.</div><div role="paragraph">Among patients who could be evaluated, a PSA<sub>50</sub> response was confirmed in 30% (73 of 243) in the olaparib group and 10% (12 of 123) in the control group. Among patients who could be evaluated, 27% (41 of 153) in the olaparib group and 10% (7 of 68) in the control group had conversion of circulating tumor cells. Results of exploratory analyses of efficacy in genomic subgroups and in patients with genes other than <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2-4"><h3>Safety</h3><div role="paragraph">The median total duration of assigned treatment for patients in the overall population (cohorts A and B) was 7.4 months (range, 0 to 22.7) in the olaparib group and 3.9 months (range, 0.6 to 19.5) in the control group. The incidence of adverse events of grade 3 or higher — irrespective of attribution, dose modification, and treatment discontinuation owing to adverse events — was higher with olaparib than with the control treatment (<a href="#t2">Table 2</a>). <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">The most common adverse events of any grade were anemia, nausea, and fatigue or asthenia with olaparib and fatigue or asthenia with the control treatment.</span> A total of 11 cases of pulmonary embolism (4% of patients) were reported in the olaparib group, as compared with 1 (1%) in the control group; none were fatal. No reports of myelodysplastic syndromes or acute myeloid leukemia were noted. Three patients reported new primary cancers: 1 in the olaparib group (glioma) and 2 in the control group (gastric cancer and transitional-cell carcinoma). One death in each group was considered by the investigators to be related to trial treatment. (For more details on safety, see the <a href="#ap2">Supplementary Appendix</a>.)</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1911440_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1911440_t2.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/ced8030a-41a1-4150-bf3d-714e209331f9/assets/images/large/nejmoa1911440_t2.jpg" height="1690" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Olaparib (N=256)</span></th><th class="txxr-borders" colspan="2"><span>Control (N=130)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">All Grades</th><th class="xxxx-borders">Grade ≥3</th><th class="xxxx-borders">All Grades</th><th class="xxxr-borders">Grade ≥3</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number (percent)</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Adverse event</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any</td><td class="xxxx-borders">244 (95)</td><td class="xxxx-borders">130 (51)</td><td class="xxxx-borders">114 (88)</td><td class="xxxr-borders">49 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anemia<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">119 (46)</td><td class="xxxx-borders shading">55 (21)</td><td class="xxxx-borders shading">20 (15)</td><td class="xxxr-borders shading">7 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">106 (41)</td><td class="xxxx-borders">3 (1)</td><td class="xxxx-borders">25 (19)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue or asthenia</td><td class="xxxx-borders shading">105 (41)</td><td class="xxxx-borders shading">7 (3)</td><td class="xxxx-borders shading">42 (32)</td><td class="xxxr-borders shading">7 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">77 (30)</td><td class="xxxx-borders">3 (1)</td><td class="xxxx-borders">23 (18)</td><td class="xxxr-borders">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">54 (21)</td><td class="xxxx-borders shading">2 (&lt;1)</td><td class="xxxx-borders shading">9 (7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">47 (18)</td><td class="xxxx-borders">6 (2)</td><td class="xxxx-borders">16 (12)</td><td class="xxxr-borders">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">45 (18)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">19 (15)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Back pain</td><td class="xxxx-borders">35 (14)</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxx-borders">15 (12)</td><td class="xxxr-borders">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders shading">32 (12)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">10 (8)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cough</td><td class="xxxx-borders">28 (11)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dyspnea</td><td class="xxxx-borders shading">26 (10)</td><td class="xxxx-borders shading">6 (2)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">24 (9)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">14 (11)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders shading">18 (7)</td><td class="xxxx-borders shading">4 (2)</td><td class="xxxx-borders shading">15 (12)</td><td class="xxxr-borders shading">5 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Interruption of intervention due to adverse event</td><td class="xxxx-borders">115 (45)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">24 (18)</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Dose reduction due to adverse event</td><td class="xxxx-borders shading">57 (22)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Discontinuation of intervention due to adverse event</td><td class="xxxx-borders">46 (18)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">11 (8)</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Death due to adverse event</td><td class="xbxx-borders shading">10 (4)</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">5 (4)</td><td class="xbxr-borders shading">NA</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events in the Overall Population (Cohorts A and B).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The table shows adverse events of any grade (≥10% of patients in either group) with corresponding adverse events of grade 3 or higher according to the Common Terminology Criteria for Adverse Events and irrespective of attribution, dose modifications owing to adverse events, and dose discontinuations owing to adverse events.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The anemia category includes anemia, decreased hemoglobin level, decreased red-cell count, decreased hematocrit level, erythropenia, macrocytic anemia, normochromic anemia, normochromic normocytic anemia, and normocytic anemia. Anemia was reported in 46% of the patients, and a decreased hemoglobin level was reported in less than 1%.</div></div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">Our findings validate phase 1 and 2 data on the antitumor activity of olaparib in metastatic castration-resistant prostate cancer.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15 r19 r22" id="body-ref-r22" href-manipulated="true">14,15,19,22</a></sup> Imaging-based progression-free survival was significantly longer in the olaparib group than in the control group among patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> (cohort A), with a 66% lower risk of disease progression or death. Prespecified subgroup analyses of baseline demographic, disease, and clinical characteristics showed a consistency of treatment effect in favor of olaparib over the control treatment. Among patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i>, an interim analysis of overall survival (secondary end point) showed a benefit for olaparib that was not significant. The survival benefit may have been obscured by the more than 80% crossover to olaparib among the patients in the control group whose disease had progressed. In addition to the imaging findings, the delay in pain progression in the olaparib group showed a direct patient benefit for olaparib as compared with the control treatment among patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i>.</div><div role="paragraph">Olaparib was also associated with a significantly longer duration of imaging-based progression-free survival than the control treatment in the overall population (patients with an alteration in any of the 15 prespecified genes), although this finding may also reflect the benefit seen in a subgroup of patients including the population with <i>BRCA1</i> or <i>BRCA2</i> alterations. This treatment benefit was supported by findings on overall survival and other clinical end points in this broader population.</div><div role="paragraph">Our results in this randomized trial are broadly consistent with preliminary observations in a small number of patients receiving rucaparib<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-2" href-manipulated="true" aria-label="Reference 13">13</a></sup> or niraparib<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-2" href-manipulated="true" aria-label="Reference 12">12</a></sup> monotherapy in similar study populations. The TOPARP-A and -B studies showed that tumors with <i>BRCA1</i> or <i>BRCA2</i> alterations were more sensitive to olaparib monotherapy than tumors harboring any of the other homologous recombination repair–related genes studied.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15-3" href-manipulated="true" aria-label="Reference 15">15</a></sup> Gene-level analyses in our trial are complex, and comparisons may be confounded by multiple considerations including sample size and treatment history; however, exploratory analyses suggest that patients with <i>BRCA1</i> or <i>BRCA2</i> alterations derived the most benefit. It is important that olaparib showed activity in patients with alterations in other prespecified genes with a direct or indirect role in homologous recombination repair; detailed analyses are ongoing.</div><div role="paragraph">Drug administration was nearly twice as long in the olaparib group as in the control group, which may have contributed to the higher incidence of certain adverse events (e.g., peripheral edema, back pain, and constipation) in the olaparib group. The safety profile of olaparib was similar to that described in other monotherapy studies.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r18" id="body-ref-r18-2" href-manipulated="true">16,18</a></sup> Pulmonary embolism is not a recognized complication of olaparib treatment, and the clinical significance of the occurrence of these cases is difficult to interpret.</div><div role="paragraph">The physician’s choice of either enzalutamide or abiraterone was selected as the comparator because switching between these agents does occur in practice, despite the lack of randomized evidence to support this approach.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-1" href-manipulated="true" aria-label="Reference 23">23</a></sup> Appropriate sequencing of the new hormonal agents is not defined, and the antitumor activity that has been reported in prospective and retrospective studies has varied.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23 r24 r25 r26 r27" id="body-ref-r27" href-manipulated="true">23-27</a></sup> Our trial included both patients who had not previously received chemotherapy and those who had, with nearly two thirds having previously received taxane therapy. Efficacy in cohort A and in the overall population was seen regardless of whether olaparib monotherapy was administered before chemotherapy or after chemotherapy.</div><div role="paragraph">In men with metastatic castration-resistant prostate cancer who had <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> mutations and who had disease progression while receiving a new hormonal agent, olaparib led to a significantly longer imaging-based progression-free survival than the physician’s choice of enzalutamide or abiraterone. A benefit was also observed in the overall trial population with an alteration in any of the 15 prespecified genes with a direct or indirect role in homologous recombination repair. The most frequent adverse events with olaparib were anemia and nausea, as previously noted with the drug.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r17 r18" id="body-ref-r18-3" href-manipulated="true">16-18</a></sup></div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on April 28, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">AstraZeneca</span> and <span class="named-content" data-type="funder">Merck Sharp &amp; Dohme</span> (a subsidiary of Merck).</div><div role="paragraph">Dr. de Bono reports receiving consulting fees and advisory board fees from Astellas Pharma, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen Global Services, Menarini Silicon Biosystems, Merck, Merck Sharp &amp; Dohme, Orion, Pfizer, Qiagen Sciences, Sanofi-Aventis U.S., Sierra Oncology, Taiho Pharmaceutical, and Vertex Pharmaceuticals and holding a patent (WO/2005/053662) on DNA damage repair inhibitors for treatment of cancer, held by the Institute of Cancer Research and licensed to AstraZeneca, and a patent (US5604213) on 17-substituted steroids useful in cancer treatment, held by the Institute of Cancer Research and licensed to Janssen Global Services; Dr. Mateo, receiving advisory board fees from Amgen, Clovis Oncology, and Janssen Pharmaceuticals, fees for serving on a speakers bureau from Astellas Pharma, and grant support and advisory board fees from AstraZeneca; Dr. Fizazi, receiving consulting fees from Astellas Pharma, Bayer, Janssen Biotech, Novartis, Orion, and Sanofi-Aventis U.S.; Dr. Saad, receiving consulting fees, advisory board fees, lecture fees, and writing assistance from Astellas Pharma, Bayer, Janssen Global Services, and Sanofi Pasteur, consulting fees and writing assistance from AstraZeneca, Bristol-Myers Squibb, Merck, and Myovant Sciences, and consulting fees, advisory board fees, and writing assistance from Pfizer; Dr. Shore, receiving consulting fees from Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Dendreon Pharmaceuticals, Ferring Pharmaceuticals, Janssen Global Services, Merck, Myovant Sciences, Nymox Pharmaceutical, Pfizer, Sanofi Pasteur Biologics, and Tolmar Pharmaceuticals; Dr. Sandhu, receiving grant support, paid to the Peter MacCallum Cancer Centre, from Amgen, Endocyte, and Genentech, grant support, paid to the Peter MacCallum Cancer Centre, and advisory fees from AstraZeneca and Merck, and advisory fees from Bristol-Myers Squibb and Merck Serono; Dr. Chi, receiving grant support, paid to BC Cancer, consulting fees, and lecture fees from Astellas Pharma, Janssen Pharmaceuticals, and Sanofi, grant support, paid to BC Cancer, and consulting fees from AstraZeneca, Bayer, and Roche, and consulting fees from Daiichi Sankyo, Pfizer, and Point Biopharma; Dr. Sartor, receiving grant support, paid to Tulane University, and consulting fees from AstraZeneca, Bayer, and Janssen Biotech and consulting fees from Clovis Oncology, Invitae, and Pfizer; Dr. Agarwal, receiving advisory board fees from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis Oncology, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen Biotech, Merck, Nektar Therapeutics, Novartis, Pfizer, Pharmacyclics (an AbbVie company), and Seattle Genetics; Dr. Olmos, receiving lecture fees, advisory board fees, and travel support from Astellas Pharma, receiving grant support, advisory board fees, and travel support from and serving on a steering committee for AstraZeneca, receiving grant support, advisory board fees, lecture fees, and travel support from Bayer HealthCare, receiving advisory board fees from Clovis Oncology and Daiichi Sankyo, serving on a steering committee for and receiving travel support from F. Hoffmann–La Roche, receiving advisory board fees from and serving on a steering committee for Genentech, receiving grant support, advisory board fees, lecture fees, and travel support from Janssen Pharmaceuticals, and receiving grant support, lecture fees, and advisory board fees from Sanofi; Dr. Thiery-Vuillemin, receiving consulting fees from Astellas Pharma, Ipsen Pharma, Janssen Biotech, Novartis, and Sanofi-Aventis U.S., consulting fees and travel support from AstraZeneca, Bristol-Myers Squibb, F. Hoffmann–La Roche, Merck Sharp &amp; Dohme, and Pfizer, and travel support from Janssen Pharmaceuticals; Dr. Twardowski, receiving lecture fees and fees for serving on a speakers bureau from Astellas Pharma and Janssen Biotech; Dr. Mehra, receiving grant support, paid to Radboud University Medical Center, and advisory fees from Astellas Pharma Europe, Janssen Pharmaceuticals, Pfizer, and Roche, advisory fees from Bristol-Myers Squibb, advisory fees and travel support from Merck Sharp &amp; Dohme, and grant support, paid to Radboud University Medical Center, from Sanofi; Drs. Goessl and Kang, being employed by and owning stock in AstraZeneca; Dr. Burgents, being employed by AstraZeneca and Merck Sharp &amp; Dohme; Dr. Wu, being employed by and owning stock in AstraZeneca; Dr. Kohlmann, being employed by and owning shares and stock options in AstraZeneca; Dr. Adelman, being employed by and owning stock in AstraZeneca; and Dr. Hussain, receiving lecture fees and travel support from Astellas Pharma, grant support, paid to Northwestern University, from AstraZeneca, grant support, paid to Northwestern University, and advisory board fees from Bayer, advisory board fees from Daiichi Sankyo, grant support, paid to Northwestern University, and advisory board fees from Genentech, grant support, paid to the University of Michigan, from Pfizer, and lecture fees from Sanofi and Genzyme. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients who participated in the PROfound trial, their families and caregivers, and our coinvestigators; Allison Allen, Ph.D., of Global Medicines Development at AstraZeneca for her role as the trial medical scientist; Claire Corcoran, Ph.D., and Caroline Sibilla, Ph.D., of Precision Medicine, AstraZeneca, for their contributions in enabling delivery of diagnostic test results in the trial; and Debbi Gorman, Ph.D., of Mudskipper Business for medical writing assistance.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1911440_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_protocol.pdf" download="nejmoa1911440_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1911440_protocol.pdf" data-doi="10.1056/NEJMoa1911440">Download</a></li><li>4.83 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1911440_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_appendix.pdf" download="nejmoa1911440_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1911440_appendix.pdf" data-doi="10.1056/NEJMoa1911440">Download</a></li><li>1.05 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1911440_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_disclosures.pdf" download="nejmoa1911440_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1911440_disclosures.pdf" data-doi="10.1056/NEJMoa1911440">Download</a></li><li>714.37 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1911440_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1911440/suppl_file/nejmoa1911440_data-sharing.pdf" download="nejmoa1911440_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1911440_data-sharing.pdf" data-doi="10.1056/NEJMoa1911440">Download</a></li><li>68.55 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. <em>JCO Precis Oncol</em> 2017 May 31 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/PO.17.00029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28825054/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000462058200038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prospective+genomic+profiling+of+prostate+cancer+across+disease+states+reveals+germline+and+somatic+alterations+that+may+affect+clinical+decision+making.&amp;publication_year=2017&amp;journal=JCO+Precis+Oncol&amp;doi=10.1200%2FPO.17.00029&amp;pmid=28825054" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a heterogeneous disease with poor outcomes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in genes involved in repairing DNA damage. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. <em>Cell</em> 2015;161:1215-1228.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2015.05.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26000489/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000355152600026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Integrative+clinical+genomics+of+advanced+prostate+cancer.&amp;publication_year=2015&amp;journal=Cell&amp;pages=1215-1228&amp;doi=10.1016%2Fj.cell.2015.05.001&amp;pmid=26000489" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a heterogeneous disease with poor outcomes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in genes involved in repairing DNA damage. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. <em>N Engl J Med</em> 2016;375:443-453.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1603144&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27433846/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380934900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inherited+DNA-repair+gene+mutations+in+men+with+metastatic+prostate+cancer.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=443-453&amp;doi=10.1056%2FNEJMoa1603144&amp;pmid=27433846" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a heterogeneous disease with poor outcomes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in genes involved in repairing DNA damage. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Beltran H, Beer TM, Carducci MA, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. <em>Eur Urol</em> 2011;60:279-290.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2011.04.038" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21592649/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000291977400027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+therapies+for+castration-resistant+prostate+cancer%3A+efficacy+and+safety.&amp;publication_year=2011&amp;journal=Eur+Urol&amp;pages=279-290&amp;doi=10.1016%2Fj.eururo.2011.04.038&amp;pmid=21592649" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Sartor O, de Bono JS. Metastatic prostate cancer. <em>N Engl J Med</em> 2018;378:645-657.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMra1701695&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29412780/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425000000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Metastatic+prostate+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=645-657&amp;doi=10.1056%2FNEJMra1701695&amp;pmid=29412780" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. <em>Eur Urol</em> 2019;75:88-99.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2018.03.028" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29673712/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452876600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Update+on+systemic+prostate+cancer+therapies%3A+management+of+metastatic+castration-resistant+prostate+cancer+in+the+era+of+precision+oncology.&amp;publication_year=2019&amp;journal=Eur+Urol&amp;pages=88-99&amp;doi=10.1016%2Fj.eururo.2018.03.028&amp;pmid=29673712" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Walsh CS. Two decades beyond <i>BRCA1</i>/<i>2</i>: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. <em>Gynecol Oncol</em> 2015;137:343-350.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ygyno.2015.02.017" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25725131/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000354504100024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Two+decades+beyond+BRCA1%2F2%3A+homologous+recombination%2C+hereditary+cancer+risk+and+a+target+for+ovarian+cancer+therapy.&amp;publication_year=2015&amp;journal=Gynecol+Oncol&amp;pages=343-350&amp;doi=10.1016%2Fj.ygyno.2015.02.017&amp;pmid=25725131" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. <em>Mol Cell</em> 2017;66:801-817.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molcel.2017.05.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28622525/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403329400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ATM%2C+ATR%2C+and+DNA-PK%3A+the+trinity+at+the+heart+of+the+DNA+damage+response.&amp;publication_year=2017&amp;journal=Mol+Cell&amp;pages=801-817&amp;doi=10.1016%2Fj.molcel.2017.05.015&amp;pmid=28622525" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. <em>J Clin Oncol</em> 2013;31:1748-1757.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2012.43.1882" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23569316/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000318766300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Germline+BRCA+mutations+are+associated+with+higher+risk+of+nodal+involvement%2C+distant+metastasis%2C+and+poor+survival+outcomes+in+prostate+cancer.&amp;publication_year=2013&amp;journal=J+Clin+Oncol&amp;pages=1748-1757&amp;doi=10.1200%2FJCO.2012.43.1882&amp;pmid=23569316" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. <em>Eur Urol</em> 2017;71:740-747.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2016.11.033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27989354/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397773300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Germline+mutations+in+ATM+and+BRCA1%2F2+distinguish+risk+for+lethal+and+indolent+prostate+cancer+and+are+associated+with+early+age+at+death.&amp;publication_year=2017&amp;journal=Eur+Urol&amp;pages=740-747&amp;doi=10.1016%2Fj.eururo.2016.11.033&amp;pmid=27989354" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Castro E, Romero-Laorden N, Del Pozo A, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. <em>J Clin Oncol</em> 2019;37:490-503.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.18.00358" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30625039/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459619000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PROREPAIR-B%3A+a+prospective+cohort+study+of+the+impact+of+germline+DNA+repair+mutations+on+the+outcomes+of+patients+with+metastatic+castration-resistant+prostate+cancer.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=490-503&amp;doi=10.1200%2FJCO.18.00358&amp;pmid=30625039" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Smith MR, Sandhu SK, Kelly WK, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. <em>J Clin Oncol</em> 2019;37:202-202. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.7_suppl.202" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30523719/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489108800243" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+study+of+niraparib+in+patients+with+metastatic+castration-resistant+prostate+cancer+%28mCRPC%29+and+biallelic+DNA-repair+gene+defects+%28DRD%29%3A+preliminary+results+of+GALAHAD.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=202-202&amp;doi=10.1200%2FJCO.2019.37.7_suppl.202&amp;pmid=30523719" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or niraparib </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Abida W, Bryce AH, Vogelzang NJ, et al. Preliminary results from TRITON2: a phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. <em>Ann Oncol</em> 2018;29:viii271-viii302.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy284.002" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459277301372" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preliminary+results+from+TRITON2%3A+a+phase+II+study+of+rucaparib+in+patients+%28pts%29+with+metastatic+castration-resistant+prostate+cancer+%28mCRPC%29+associated+with+homologous+recombination+repair+%28HRR%29+gene+alterations.&amp;publication_year=2018&amp;journal=Ann+Oncol&amp;pages=viii271-viii302&amp;doi=10.1093%2Fannonc%2Fmdy284.002" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] number of patients receiving rucaparib </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. <em>N Engl J Med</em> 2015;373:1697-1708.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_15_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1506859&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26510020/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363514100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA-repair+defects+and+olaparib+in+metastatic+prostate+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1697-1708&amp;doi=10.1056%2FNEJMoa1506859&amp;pmid=26510020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] castration-resistant prostate cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <em>Lancet Oncol</em> 2020;21:162-174.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(19)30684-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31806540/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505211900062" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Olaparib+in+patients+with+metastatic+castration-resistant+prostate+cancer+with+DNA+repair+gene+aberrations+%28TOPARP-B%29%3A+a+multicentre%2C+open-label%2C+randomised%2C+phase+2+trial.&amp;publication_year=2020&amp;journal=Lancet+Oncol&amp;pages=162-174&amp;doi=10.1016%2FS1470-2045%2819%2930684-9&amp;pmid=31806540" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] castration-resistant prostate cancer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] recombination repair–related genes studied. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline <i>BRCA</i> mutation. <em>N Engl J Med</em> 2017;377:523-533.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_17_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1706450&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28578601/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407212600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Olaparib+for+metastatic+breast+cancer+in+patients+with+a+germline+BRCA+mutation.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=523-533&amp;doi=10.1056%2FNEJMoa1706450&amp;pmid=28578601" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] described in other monotherapy studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] nausea, as previously noted with the drug. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline <i>BRCA</i>-mutated metastatic pancreatic cancer. <em>N Engl J Med</em> 2019;381:317-327.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1903387&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31157963/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000477993600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Maintenance+olaparib+for+germline+BRCA-mutated+metastatic+pancreatic+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=317-327&amp;doi=10.1056%2FNEJMoa1903387&amp;pmid=31157963" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] nausea, as previously noted with the drug. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. <em>N Engl J Med</em> 2018;379:2495-2505.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1810858&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30345884/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454351100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Maintenance+olaparib+in+patients+with+newly+diagnosed+advanced+ovarian+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2495-2505&amp;doi=10.1056%2FNEJMoa1810858&amp;pmid=30345884" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] described in other monotherapy studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] nausea, as previously noted with the drug. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. <em>J Clin Oncol</em> 2015;33:244-250.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2014.56.2728" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25366685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000352421400008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Olaparib+monotherapy+in+patients+with+advanced+cancer+and+a+germline+BRCA1%2F2+mutation.&amp;publication_year=2015&amp;journal=J+Clin+Oncol&amp;pages=244-250&amp;doi=10.1200%2FJCO.2014.56.2728&amp;pmid=25366685" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] castration-resistant prostate cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">O’Connor MJ. Targeting the DNA damage response in cancer. <em>Mol Cell</em> 2015;60:547-560.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molcel.2015.10.040" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26590714/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000368288700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+the+DNA+damage+response+in+cancer.&amp;publication_year=2015&amp;journal=Mol+Cell&amp;pages=547-560&amp;doi=10.1016%2Fj.molcel.2015.10.040&amp;pmid=26590714" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. <em>Biometrics</em> 1979;35:549-556.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2307/2530245" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/497341/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1979HM72500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+multiple+testing+procedure+for+clinical+trials.&amp;publication_year=1979&amp;journal=Biometrics&amp;pages=549-556&amp;doi=10.2307%2F2530245&amp;pmid=497341" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. <em>N Engl J Med</em> 2009;361:123-134.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa0900212&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19553641/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000267748900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+poly%28ADP-ribose%29+polymerase+in+tumors+from+BRCA+mutation+carriers.&amp;publication_year=2009&amp;journal=N+Engl+J+Med&amp;pages=123-134&amp;doi=10.1056%2FNEJMoa0900212&amp;pmid=19553641" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">de Bono JS, Chowdhury S, Feyerabend S, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe. <em>Eur Urol</em> 2018;74:37-45.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2017.07.035" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28844372/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436486900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antitumour+activity+and+safety+of+enzalutamide+in+patients+with+metastatic+castration-resistant+prostate+cancer+previously+treated+with+abiraterone+acetate+plus+prednisone+for+%E2%89%A524+weeks+in+Europe.&amp;publication_year=2018&amp;journal=Eur+Urol&amp;pages=37-45&amp;doi=10.1016%2Fj.eururo.2017.07.035&amp;pmid=28844372" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] evidence to support this approach. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and retrospective studies has varied. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Khalaf D, Annala M, Finch DL, et al. Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): results for 2nd-line therapy. <em>J Clin Oncol</em> 2018;36:5015-5015.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.5015" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000442916002126" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+2+randomized+cross-over+trial+of+abiraterone+%2B+prednisone+%28ABI%2BP%29+vs+enzalutamide+%28ENZ%29+for+patients+%28pts%29+with+metastatic+castration+resistant+prostate+cancer+%28mCPRC%29%3A+results+for+2nd-line+therapy.&amp;publication_year=2018&amp;journal=J+Clin+Oncol&amp;pages=5015-5015&amp;doi=10.1200%2FJCO.2018.36.15_suppl.5015" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Terada N, Maughan BL, Akamatsu S, et al. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. <em>Int J Urol</em> 2017;24:441-448.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/iju.13346" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28455853/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405209900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Exploring+the+optimal+sequence+of+abiraterone+and+enzalutamide+in+patients+with+chemotherapy-na%C3%AFve+castration-resistant+prostate+cancer%3A+the+Kyoto-Baltimore+collaboration.&amp;publication_year=2017&amp;journal=Int+J+Urol&amp;pages=441-448&amp;doi=10.1111%2Fiju.13346&amp;pmid=28455853" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Matsubara N, Yamada Y, Tabata KI, et al. Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. <em>Clin Genitourin Cancer</em> 2018;16:142-148.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.clgc.2017.09.008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29042308/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428941100039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Abiraterone+followed+by+enzalutamide+versus+enzalutamide+followed+by+abiraterone+in+chemotherapy-naive+patients+with+metastatic+castration-resistant+prostate+cancer.&amp;publication_year=2018&amp;journal=Clin+Genitourin+Cancer&amp;pages=142-148&amp;doi=10.1016%2Fj.clgc.2017.09.008&amp;pmid=29042308" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. <em>Prostate</em> 2017;77:33-40.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pros.23246" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27527643/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000390336000004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparing+sequencing+of+abiraterone+and+enzalutamide+in+men+with+metastatic+castration-resistant+prostate+cancer%3A+a+retrospective+study.&amp;publication_year=2017&amp;journal=Prostate&amp;pages=33-40&amp;doi=10.1002%2Fpros.23246&amp;pmid=27527643" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/382/22"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">382</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">22</span></span> • <span property="datePublished">May 28, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2091</span>-<span property="pageEnd">2102</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: April 28, 2020</div><div><b class="core-label">Published in issue</b>: May 28, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/urology-prostate-disease-general" alt="View article keyword Urology/Prostate Disease General" data-interactiontype="article_recirculation_click">Urology/Prostate Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Johann</span> <span property="familyName">de Bono</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2034-595X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-2034-595X</a></span>, <span property="author" typeof="Person"><span property="givenName">Joaquin</span> <span property="familyName">Mateo</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Karim</span> <span property="familyName">Fizazi</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fred</span> <span property="familyName">Saad</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Neal</span> <span property="familyName">Shore</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shahneen</span> <span property="familyName">Sandhu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kim N.</span> <span property="familyName">Chi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Oliver</span> <span property="familyName">Sartor</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-8777-7343" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-8777-7343</a></span>, <span property="author" typeof="Person"><span property="givenName">Neeraj</span> <span property="familyName">Agarwal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Olmos</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Antoine</span> <span property="familyName">Thiery-Vuillemin</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Przemyslaw</span> <span property="familyName">Twardowski</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Niven</span> <span property="familyName">Mehra</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carsten</span> <span property="familyName">Goessl</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jinyu</span> <span property="familyName">Kang</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joseph</span> <span property="familyName">Burgents</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wenting</span> <span property="familyName">Wu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alexander</span> <span property="familyName">Kohlmann</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carrie A.</span> <span property="familyName">Adelman</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Maha</span> <span property="familyName">Hussain</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) — all in the United Kingdom; Vall d’Hebron Institute of Oncology and Vall d’Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) — all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) — all in France; Centre Hospitalier de l’Université de Montréal–Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) — all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. de Bono at the Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom, or at <a href="mailto:johann.de-bono@icr.ac.uk">johann.de-bono@icr.ac.uk</a>.</div><div role="doc-footnote"><div id="fn1" role="paragraph">A list of the investigators in the PROfound trial is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">1642</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1911440" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="1b0d129a-7837-2118-da88-f5672a9cb6df"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985" style="display:inline-block;">
                <img alt="Article has an altmetric score of 984" src="https://badges.altmetric.com/?size=320&amp;score=984&amp;types=mabctwf1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_1b0d129a-7837-2118-da88-f5672a9cb6df" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=news">
          Picked up by <b>96</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=twitter">
          Posted by <b>393</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=patents">
          Referenced in <b>8</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=80788985&amp;tab=guidelines">
          Referenced in <b>6</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>819</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d62e2bb47e1d0f-GRU"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1911440"> <input type="hidden" name="downloadFileName" value="csp_382_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1911440%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-22%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="1642" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mokhtar Rejili, </li></ul><span class="cited-by__entry__title">Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy, </span><span class="cited-by__entry__series-title">Pathology - Research and Practice, </span><span class="cited-by__entry__volume"><strong>272</strong>, </span><span class="cited-by__entry__page-range">(156075), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.prp.2025.156075" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.prp.2025.156075</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.prp.2025.156075" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shanhui Liu, </li><li class="list-inline-item cited-by__entry__author">Shengjun Fu, </li><li class="list-inline-item cited-by__entry__author">Xuewu Wu, </li><li class="list-inline-item cited-by__entry__author">Shan Wu, </li><li class="list-inline-item cited-by__entry__author">Youli Zhao, </li><li class="list-inline-item cited-by__entry__author">Xinyue Wu, </li><li class="list-inline-item cited-by__entry__author">Liting Yan, </li><li class="list-inline-item cited-by__entry__author">Jianzhong Lu, </li><li class="list-inline-item cited-by__entry__author">Lanlan Li, </li><li class="list-inline-item cited-by__entry__author">Yan Tao, </li></ul><span class="cited-by__entry__title">TAK-901, a novel EPHA2 inhibitor as a therapeutic strategy against prostate cancer, </span><span class="cited-by__entry__series-title">Cellular Signalling, </span><span class="cited-by__entry__volume"><strong>131</strong>, </span><span class="cited-by__entry__page-range">(111750), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.cellsig.2025.111750" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.cellsig.2025.111750</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.cellsig.2025.111750" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yohei Okuda, </li><li class="list-inline-item cited-by__entry__author">Taigo Kato, </li><li class="list-inline-item cited-by__entry__author">Yu Ishizuya, </li><li class="list-inline-item cited-by__entry__author">Takuji Hayashi, </li><li class="list-inline-item cited-by__entry__author">Yoshiyuki Yamamoto, </li><li class="list-inline-item cited-by__entry__author">Koji Hatano, </li><li class="list-inline-item cited-by__entry__author">Atsunari Kawashima, </li><li class="list-inline-item cited-by__entry__author">Junko Murai, </li><li class="list-inline-item cited-by__entry__author">Norio Nonomura, </li></ul><span class="cited-by__entry__title">
                  PARP
              Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer
            , </span><span class="cited-by__entry__series-title">International Journal of Urology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/iju.70100" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/iju.70100</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/iju.70100" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yuh-Ren Kuo, </li><li class="list-inline-item cited-by__entry__author">Zhi-Jun Zhu, </li><li class="list-inline-item cited-by__entry__author">Hau-Chern Jan, </li><li class="list-inline-item cited-by__entry__author">Che-Yuan Hu, </li><li class="list-inline-item cited-by__entry__author">Yin-Chien Ou, </li><li class="list-inline-item cited-by__entry__author">Chien-Hui Ou, </li><li class="list-inline-item cited-by__entry__author">Yuh-Shyan Tsai, </li><li class="list-inline-item cited-by__entry__author">Kuan-Yu Wu, </li></ul><span class="cited-by__entry__title">Alkaline phosphatase and platelet-to-lymphocyte ratio changes after initial radium-223 administration as predictors of overall survival in metastatic castration-resistant prostate cancer patients treated with radium-223, </span><span class="cited-by__entry__series-title">Urological Science, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/us9.0000000000000081" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/us9.0000000000000081</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/us9.0000000000000081" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Olivia Steenbock, </li><li class="list-inline-item cited-by__entry__author">Axel Heidenreich, </li></ul><span class="cited-by__entry__title">Kastrationsresistentes Prostatakarzinom: Therapie mit PARP-Inhibitoren in der metastasierten Situation, </span><span class="cited-by__entry__series-title">Trillium Krebsmedizin, </span><span class="cited-by__entry__volume"><strong>34</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(155-161), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.47184/tk.2025.02.6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.47184/tk.2025.02.6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.47184/tk.2025.02.6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sabine Siegert, </li><li class="list-inline-item cited-by__entry__author">Christopher Poremba, </li></ul><span class="cited-by__entry__title">Prostate Carcinoma: Hereditary and Predictive Aspects of Molecular Pathology, </span><span class="cited-by__entry__series-title">Trillium Pathology, </span><span class="cited-by__entry__volume"><strong>4</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.47184/tp.2025.01.05" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.47184/tp.2025.01.05</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.47184/tp.2025.01.05" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wassim Abida, </li><li class="list-inline-item cited-by__entry__author">Himisha Beltran, </li><li class="list-inline-item cited-by__entry__author">Ruben Raychaudhuri, </li></ul><span class="cited-by__entry__title">State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer, </span><span class="cited-by__entry__series-title">American Society of Clinical Oncology Educational Book, </span><span class="cited-by__entry__volume"><strong>45</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/EDBK-25-473636" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/EDBK-25-473636</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/EDBK-25-473636" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Laura Segalés, </li><li class="list-inline-item cited-by__entry__author">Joaquim Bellmunt, </li><li class="list-inline-item cited-by__entry__author">Júlia Perera-Bel, </li><li class="list-inline-item cited-by__entry__author">Gardenia Vargas-Parra, </li><li class="list-inline-item cited-by__entry__author">Nuria Juanpere, </li><li class="list-inline-item cited-by__entry__author">David López, </li><li class="list-inline-item cited-by__entry__author">Alejo Rodriguez-Vida, </li><li class="list-inline-item cited-by__entry__author">Lluís Colomo, </li><li class="list-inline-item cited-by__entry__author">Lluís Cecchini, </li><li class="list-inline-item cited-by__entry__author">Josep Lloreta-Trull, </li><li class="list-inline-item cited-by__entry__author">José Yélamos, </li><li class="list-inline-item cited-by__entry__author">Lluís Fumadó, </li><li class="list-inline-item cited-by__entry__author">Silvia Hernández-Llodrà, </li></ul><span class="cited-by__entry__title">Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer, </span><span class="cited-by__entry__series-title">Laboratory Investigation, </span><span class="cited-by__entry__volume"><strong>105</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(104171), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.labinv.2025.104171" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.labinv.2025.104171</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.labinv.2025.104171" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Syed Arsalan Ahmed Naqvi, </li><li class="list-inline-item cited-by__entry__author">Irbaz Bin Riaz, </li><li class="list-inline-item cited-by__entry__author">Arifa Bibi, </li><li class="list-inline-item cited-by__entry__author">Muhammad Ali Khan, </li><li class="list-inline-item cited-by__entry__author">Manal Imran, </li><li class="list-inline-item cited-by__entry__author">Kaneez Zahra Rubab Khakwani, </li><li class="list-inline-item cited-by__entry__author">Ammad Raina, </li><li class="list-inline-item cited-by__entry__author">Muhammad Umair Anjum, </li><li class="list-inline-item cited-by__entry__author">Ewan K. Cobran, </li><li class="list-inline-item cited-by__entry__author">Jeremy L. Warner, </li><li class="list-inline-item cited-by__entry__author">Syed A. Hussain, </li><li class="list-inline-item cited-by__entry__author">Parminder Singh, </li><li class="list-inline-item cited-by__entry__author">Daniel S. Childs, </li><li class="list-inline-item cited-by__entry__author">Sylvan C. Baca, </li><li class="list-inline-item cited-by__entry__author">Jacob J. Orme, </li><li class="list-inline-item cited-by__entry__author">Joaquin Mateo, </li><li class="list-inline-item cited-by__entry__author">Neeraj Agarwal, </li><li class="list-inline-item cited-by__entry__author">Silke Gillessen, </li><li class="list-inline-item cited-by__entry__author">Mohammad Hassan Murad, </li><li class="list-inline-item cited-by__entry__author">Oliver Sartor, </li><li class="list-inline-item cited-by__entry__author">Alan H. Bryce, </li></ul><span class="cited-by__entry__title">Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis, </span><span class="cited-by__entry__series-title">European Urology, </span><span class="cited-by__entry__volume"><strong>87</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(626-640), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.eururo.2024.12.007" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.eururo.2024.12.007</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.eururo.2024.12.007" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Stacy Loeb, </li><li class="list-inline-item cited-by__entry__author">Susan T. Vadaparampil, </li><li class="list-inline-item cited-by__entry__author">Veda N. Giri, </li></ul><span class="cited-by__entry__title">Germline testing for prostate cancer: current state and opportunities for enhanced access, </span><span class="cited-by__entry__series-title">eBioMedicine, </span><span class="cited-by__entry__volume"><strong>116</strong>, </span><span class="cited-by__entry__page-range">(105705), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ebiom.2025.105705" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ebiom.2025.105705</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ebiom.2025.105705" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1911440%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-22%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1911440" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1911440" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1911440.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f1.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/b3186816-8d37-4708-afa5-bb563ae2327c/assets/images/large/nejmoa1911440_f1.jpg" height="3438" width="2632" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Estimates of Imaging-Based Progression-free Survival and Interim Overall Survival.</div><div class="notes"><div role="doc-footnote">Panel A shows imaging-based progression-free survival, as assessed by blinded independent central review, in patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> (cohort A), who received either olaparib or the physician’s choice of enzalutamide or abiraterone (control group); Panel B shows interim overall survival in the same cohort. For patients with censored data in cohort A, the median duration of follow-up for imaging-based progression-free survival was 7.5 months in the olaparib group and 5.4 months in the control group; the median duration of follow-up for overall survival was 12.6 months and 13.2 months, respectively. Panel C shows imaging-based progression-free survival in cohorts A and B (overall population); patients in cohort B had alterations in any of 12 other prespecified genes. For patients with censored data in the overall population, the median duration of follow-up for imaging-based progression-free survival was 7.4 months in the olaparib group and 5.5 months in the control group. Overall, at the time of the analysis of imaging-based progression-free survival by blinded independent central review, 10 patients (4%) in the olaparib group and 8 (6%) in the control group had withdrawn consent, and their data were censored. (For interim overall survival in the overall population, see Fig. S3.)</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f2.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/840a7eee-0ab3-4666-9097-666025b6c990/assets/images/large/nejmoa1911440_f2.jpg" height="1671" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Prespecified Subgroup Analysis of Imaging-Based Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Shown is the subgroup analysis of patients in cohort A (Panel A) and those in the overall population (cohorts A and B) (Panel B). Subgroups in which fewer than five progression events or deaths occurred per group were not included in the analysis. The sizes of the circles are proportional to the number of events. The dashed line indicates the point of no effect (hazard ratio, 1.00). A hazard ratio of less than 1.00 favors olaparib. ECOG denotes Eastern Cooperative Oncology Group, and PSA prostate-specific antigen.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f3.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/5ff1be9a-2097-455a-83b5-e1e60cddd366/assets/images/large/nejmoa1911440_f3.jpg" height="2507" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Time to Pain Progression.</div><div class="notes"><div role="doc-footnote">Shown is the probability that patients had no progression of pain during treatment with olaparib or the control drug in cohort A (Panel A) and in cohorts A and B (Panel B). In this analysis, death was not considered as a competing risk. Time to pain progression was based on the worst-pain score (item 3) on the Brief Pain Inventory–Short Form and on opioid use.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1911440_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1911440/asset/a216352e-de54-484c-a212-a2e6a4ff90d1/assets/images/large/nejmoa1911440_t1.jpg" height="2661" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Cohort A</span></th><th class="txxr-borders" colspan="2"><span>Cohorts A and B</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Olaparib<br>(N=162)</th><th class="xxxx-borders">Control<br>(N=83)</th><th class="xxxx-borders">Olaparib<br>(N=256)</th><th class="xxxr-borders">Control<br>(N=131)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age at randomization (range) — yr</td><td class="xxxx-borders shading">68 (47–86)</td><td class="xxxx-borders shading">67 (49–86)</td><td class="xxxx-borders shading">69 (47–91)</td><td class="xxxr-borders shading">69 (49–87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Age ≥65 yr at randomization — no. (%)</td><td class="xxxx-borders">108 (67)</td><td class="xxxx-borders">60 (72)</td><td class="xxxx-borders">174 (68)</td><td class="xxxr-borders">97 (74)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Metastatic disease at initial diagnosis — no. (%)</td><td class="xxxx-borders shading">38 (23)</td><td class="xxxx-borders shading">19 (23)</td><td class="xxxx-borders shading">66 (26)</td><td class="xxxr-borders shading">25 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Missing data</td><td class="xxxx-borders">7 (4)</td><td class="xxxx-borders">4 (5)</td><td class="xxxx-borders">11 (4)</td><td class="xxxr-borders">7 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Gleason score ≥8 — no./total no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">105/157 (67)</td><td class="xxxx-borders shading">54/80 (67)</td><td class="xxxx-borders shading">183/251 (73)</td><td class="xxxr-borders shading">95/127 (75)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Patients with alterations in a single gene — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>BRCA1</i></td><td class="xxxx-borders shading">8 (5)</td><td class="xxxx-borders shading">5 (6)</td><td class="xxxx-borders shading">8 (3)</td><td class="xxxr-borders shading">5 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>BRCA2</i></td><td class="xxxx-borders">80 (49)</td><td class="xxxx-borders">47 (57)</td><td class="xxxx-borders">81 (32)</td><td class="xxxr-borders">47 (36)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>ATM</i></td><td class="xxxx-borders shading">60 (37)</td><td class="xxxx-borders shading">24 (29)</td><td class="xxxx-borders shading">62 (24)</td><td class="xxxr-borders shading">24 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>CDK12</i></td><td class="xxxx-borders">NA</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">61 (24)</td><td class="xxxr-borders">28 (21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median PSA at baseline (IQR) — μg/liter</td><td class="xxxx-borders shading">62.2<br>(21.9–280.4)</td><td class="xxxx-borders shading">112.9<br>(34.3–317.1)</td><td class="xxxx-borders shading">68.2<br>(24.1–294.4)</td><td class="xxxr-borders shading">106.5<br>(37.2–326.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Measurable disease at baseline — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">95 (59)</td><td class="xxxx-borders">46 (55)</td><td class="xxxx-borders">149 (58)</td><td class="xxxr-borders">72 (55)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Metastases at baseline — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Bone only</td><td class="xxxx-borders">57 (35)</td><td class="xxxx-borders">23 (28)</td><td class="xxxx-borders">86 (34)</td><td class="xxxr-borders">38 (29)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Visceral: lung or liver</td><td class="xxxx-borders shading">46 (28)</td><td class="xxxx-borders shading">32 (39)</td><td class="xxxx-borders shading">68 (27)</td><td class="xxxr-borders shading">44 (34)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">49 (30)</td><td class="xxxx-borders">23 (28)</td><td class="xxxx-borders">88 (34)</td><td class="xxxr-borders">41 (31)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance status — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">84 (52)</td><td class="xxxx-borders">34 (41)</td><td class="xxxx-borders">131 (51)</td><td class="xxxr-borders">55 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">67 (41)</td><td class="xxxx-borders shading">46 (55)</td><td class="xxxx-borders shading">112 (44)</td><td class="xxxr-borders shading">71 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">2</td><td class="xxxx-borders">11 (7)</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">13 (5)</td><td class="xxxr-borders">4 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Missing data</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Previous new hormonal agent — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Enzalutamide only</td><td class="xxxx-borders shading">68 (42)</td><td class="xxxx-borders shading">40 (48)</td><td class="xxxx-borders shading">105 (41)</td><td class="xxxr-borders shading">54 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Abiraterone only</td><td class="xxxx-borders">62 (38)</td><td class="xxxx-borders">29 (35)</td><td class="xxxx-borders">100 (39)</td><td class="xxxr-borders">54 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Enzalutamide and abiraterone</td><td class="xxxx-borders shading">32 (20)</td><td class="xxxx-borders shading">14 (17)</td><td class="xxxx-borders shading">51 (20)</td><td class="xxxr-borders shading">23 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Previous taxane use — no. (%)</td><td class="xxxx-borders">106 (65)</td><td class="xxxx-borders">52 (63)</td><td class="xxxx-borders">170 (66)</td><td class="xxxr-borders">84 (64)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Docetaxel only</td><td class="xxxx-borders shading">74 (46)</td><td class="xxxx-borders shading">32 (39)</td><td class="xxxx-borders shading">115 (45)</td><td class="xxxr-borders shading">58 (44)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cabazitaxel only</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Docetaxel and cabazitaxel</td><td class="xxxx-borders shading">29 (18)</td><td class="xxxx-borders shading">20 (24)</td><td class="xxxx-borders shading">51 (20)</td><td class="xxxr-borders shading">26 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Paclitaxel only</td><td class="xbxx-borders">1 (&lt;1)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (&lt;1)</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Cohort A included patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i>. Cohort B included patient with alterations in any of 12 other prespecified genes: <i>BRIP1</i>, <i>BARD1</i>, <i>CDK12</i>, <i>CHEK1</i>, <i>CHEK2</i>, <i>FANCL</i>, <i>PALB2</i>, <i>PPP2R2A</i>, <i>RAD51B</i>, <i>RAD51C</i>, <i>RAD51D</i>, and <i>RAD54L</i>. In both cohorts, patients in the control group received the physician’s choice of enzalutamide or abiraterone. ECOG denotes Eastern Cooperative Oncology Group, IQR interquartile range, NA not applicable, and PSA prostate-specific antigen.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">In general, scores on the Gleason scale range from 6 to 10, with higher scores indicating a worse prognosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">A total of 28 patients (21 in cohort A and 7 in cohort B) had mutations in more than one gene. A total of 4 patients were incorrectly assigned to cohort B (1 in the olaparib group had an alteration in <i>BRCA2</i>, 1 in the control group had alterations in <i>BRCA2</i> and <i>CDK12</i>, and 2 in the olaparib group had alterations in <i>ATM</i>).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Data were derived from electronic case-report forms as assessed by the investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">A total of 13 patients received a new hormonal agent for disease before a diagnosis of metastatic castration-resistant prostate cancer; all others received a new hormonal agent after the development of metastatic castration-resistant prostate cancer.</div></div></div></figcaption></a><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1911440_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1911440_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1911440/asset/ced8030a-41a1-4150-bf3d-714e209331f9/assets/images/large/nejmoa1911440_t2.jpg" height="1690" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Olaparib (N=256)</span></th><th class="txxr-borders" colspan="2"><span>Control (N=130)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">All Grades</th><th class="xxxx-borders">Grade ≥3</th><th class="xxxx-borders">All Grades</th><th class="xxxr-borders">Grade ≥3</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number (percent)</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Adverse event</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any</td><td class="xxxx-borders">244 (95)</td><td class="xxxx-borders">130 (51)</td><td class="xxxx-borders">114 (88)</td><td class="xxxr-borders">49 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anemia<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">119 (46)</td><td class="xxxx-borders shading">55 (21)</td><td class="xxxx-borders shading">20 (15)</td><td class="xxxr-borders shading">7 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">106 (41)</td><td class="xxxx-borders">3 (1)</td><td class="xxxx-borders">25 (19)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue or asthenia</td><td class="xxxx-borders shading">105 (41)</td><td class="xxxx-borders shading">7 (3)</td><td class="xxxx-borders shading">42 (32)</td><td class="xxxr-borders shading">7 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">77 (30)</td><td class="xxxx-borders">3 (1)</td><td class="xxxx-borders">23 (18)</td><td class="xxxr-borders">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">54 (21)</td><td class="xxxx-borders shading">2 (&lt;1)</td><td class="xxxx-borders shading">9 (7)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">47 (18)</td><td class="xxxx-borders">6 (2)</td><td class="xxxx-borders">16 (12)</td><td class="xxxr-borders">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">45 (18)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">19 (15)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Back pain</td><td class="xxxx-borders">35 (14)</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxx-borders">15 (12)</td><td class="xxxr-borders">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders shading">32 (12)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">10 (8)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Cough</td><td class="xxxx-borders">28 (11)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dyspnea</td><td class="xxxx-borders shading">26 (10)</td><td class="xxxx-borders shading">6 (2)</td><td class="xxxx-borders shading">4 (3)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">24 (9)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">14 (11)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders shading">18 (7)</td><td class="xxxx-borders shading">4 (2)</td><td class="xxxx-borders shading">15 (12)</td><td class="xxxr-borders shading">5 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Interruption of intervention due to adverse event</td><td class="xxxx-borders">115 (45)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">24 (18)</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Dose reduction due to adverse event</td><td class="xxxx-borders shading">57 (22)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">5 (4)</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Discontinuation of intervention due to adverse event</td><td class="xxxx-borders">46 (18)</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">11 (8)</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Death due to adverse event</td><td class="xbxx-borders shading">10 (4)</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">5 (4)</td><td class="xbxr-borders shading">NA</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The table shows adverse events of any grade (≥10% of patients in either group) with corresponding adverse events of grade 3 or higher according to the Common Terminology Criteria for Adverse Events and irrespective of attribution, dose modifications owing to adverse events, and dose discontinuations owing to adverse events.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The anemia category includes anemia, decreased hemoglobin level, decreased red-cell count, decreased hematocrit level, erythropenia, macrocytic anemia, normochromic anemia, normochromic normocytic anemia, and normocytic anemia. Anemia was reported in 46% of the patients, and a decreased hemoglobin level was reported in less than 1%.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events in the Overall Population (Cohorts A and B).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1911440_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1911440</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. <em>JCO Precis Oncol</em> 2017 May 31 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/PO.17.00029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28825054/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000462058200038" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prospective+genomic+profiling+of+prostate+cancer+across+disease+states+reveals+germline+and+somatic+alterations+that+may+affect+clinical+decision+making.&amp;publication_year=2017&amp;journal=JCO+Precis+Oncol&amp;doi=10.1200%2FPO.17.00029&amp;pmid=28825054" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a heterogeneous disease with poor outcomes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in genes involved in repairing DNA damage. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. <em>Cell</em> 2015;161:1215-1228.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2015.05.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26000489/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000355152600026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Integrative+clinical+genomics+of+advanced+prostate+cancer.&amp;publication_year=2015&amp;journal=Cell&amp;pages=1215-1228&amp;doi=10.1016%2Fj.cell.2015.05.001&amp;pmid=26000489" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a heterogeneous disease with poor outcomes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in genes involved in repairing DNA damage. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. <em>N Engl J Med</em> 2016;375:443-453.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1603144&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27433846/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380934900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inherited+DNA-repair+gene+mutations+in+men+with+metastatic+prostate+cancer.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=443-453&amp;doi=10.1056%2FNEJMoa1603144&amp;pmid=27433846" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] a heterogeneous disease with poor outcomes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in genes involved in repairing DNA damage. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Beltran H, Beer TM, Carducci MA, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. <em>Eur Urol</em> 2011;60:279-290.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2011.04.038" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21592649/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000291977400027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+therapies+for+castration-resistant+prostate+cancer%3A+efficacy+and+safety.&amp;publication_year=2011&amp;journal=Eur+Urol&amp;pages=279-290&amp;doi=10.1016%2Fj.eururo.2011.04.038&amp;pmid=21592649" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Sartor O, de Bono JS. Metastatic prostate cancer. <em>N Engl J Med</em> 2018;378:645-657.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMra1701695&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29412780/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425000000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Metastatic+prostate+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=645-657&amp;doi=10.1056%2FNEJMra1701695&amp;pmid=29412780" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. <em>Eur Urol</em> 2019;75:88-99.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2018.03.028" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29673712/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452876600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Update+on+systemic+prostate+cancer+therapies%3A+management+of+metastatic+castration-resistant+prostate+cancer+in+the+era+of+precision+oncology.&amp;publication_year=2019&amp;journal=Eur+Urol&amp;pages=88-99&amp;doi=10.1016%2Fj.eururo.2018.03.028&amp;pmid=29673712" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Walsh CS. Two decades beyond <i>BRCA1</i>/<i>2</i>: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. <em>Gynecol Oncol</em> 2015;137:343-350.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ygyno.2015.02.017" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25725131/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000354504100024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Two+decades+beyond+BRCA1%2F2%3A+homologous+recombination%2C+hereditary+cancer+risk+and+a+target+for+ovarian+cancer+therapy.&amp;publication_year=2015&amp;journal=Gynecol+Oncol&amp;pages=343-350&amp;doi=10.1016%2Fj.ygyno.2015.02.017&amp;pmid=25725131" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. <em>Mol Cell</em> 2017;66:801-817.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molcel.2017.05.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28622525/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403329400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ATM%2C+ATR%2C+and+DNA-PK%3A+the+trinity+at+the+heart+of+the+DNA+damage+response.&amp;publication_year=2017&amp;journal=Mol+Cell&amp;pages=801-817&amp;doi=10.1016%2Fj.molcel.2017.05.015&amp;pmid=28622525" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. <em>J Clin Oncol</em> 2013;31:1748-1757.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2012.43.1882" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23569316/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000318766300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Germline+BRCA+mutations+are+associated+with+higher+risk+of+nodal+involvement%2C+distant+metastasis%2C+and+poor+survival+outcomes+in+prostate+cancer.&amp;publication_year=2013&amp;journal=J+Clin+Oncol&amp;pages=1748-1757&amp;doi=10.1200%2FJCO.2012.43.1882&amp;pmid=23569316" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. <em>Eur Urol</em> 2017;71:740-747.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2016.11.033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27989354/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397773300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Germline+mutations+in+ATM+and+BRCA1%2F2+distinguish+risk+for+lethal+and+indolent+prostate+cancer+and+are+associated+with+early+age+at+death.&amp;publication_year=2017&amp;journal=Eur+Urol&amp;pages=740-747&amp;doi=10.1016%2Fj.eururo.2016.11.033&amp;pmid=27989354" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Castro E, Romero-Laorden N, Del Pozo A, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. <em>J Clin Oncol</em> 2019;37:490-503.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.18.00358" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30625039/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459619000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PROREPAIR-B%3A+a+prospective+cohort+study+of+the+impact+of+germline+DNA+repair+mutations+on+the+outcomes+of+patients+with+metastatic+castration-resistant+prostate+cancer.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=490-503&amp;doi=10.1200%2FJCO.18.00358&amp;pmid=30625039" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Smith MR, Sandhu SK, Kelly WK, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. <em>J Clin Oncol</em> 2019;37:202-202. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.7_suppl.202" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30523719/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489108800243" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+study+of+niraparib+in+patients+with+metastatic+castration-resistant+prostate+cancer+%28mCRPC%29+and+biallelic+DNA-repair+gene+defects+%28DRD%29%3A+preliminary+results+of+GALAHAD.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=202-202&amp;doi=10.1200%2FJCO.2019.37.7_suppl.202&amp;pmid=30523719" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] or niraparib </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Abida W, Bryce AH, Vogelzang NJ, et al. Preliminary results from TRITON2: a phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. <em>Ann Oncol</em> 2018;29:viii271-viii302.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy284.002" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459277301372" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Preliminary+results+from+TRITON2%3A+a+phase+II+study+of+rucaparib+in+patients+%28pts%29+with+metastatic+castration-resistant+prostate+cancer+%28mCRPC%29+associated+with+homologous+recombination+repair+%28HRR%29+gene+alterations.&amp;publication_year=2018&amp;journal=Ann+Oncol&amp;pages=viii271-viii302&amp;doi=10.1093%2Fannonc%2Fmdy284.002" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] number of patients receiving rucaparib </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. <em>N Engl J Med</em> 2015;373:1697-1708.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_15_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1506859&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26510020/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363514100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA-repair+defects+and+olaparib+in+metastatic+prostate+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1697-1708&amp;doi=10.1056%2FNEJMoa1506859&amp;pmid=26510020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] castration-resistant prostate cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <em>Lancet Oncol</em> 2020;21:162-174.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(19)30684-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31806540/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505211900062" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Olaparib+in+patients+with+metastatic+castration-resistant+prostate+cancer+with+DNA+repair+gene+aberrations+%28TOPARP-B%29%3A+a+multicentre%2C+open-label%2C+randomised%2C+phase+2+trial.&amp;publication_year=2020&amp;journal=Lancet+Oncol&amp;pages=162-174&amp;doi=10.1016%2FS1470-2045%2819%2930684-9&amp;pmid=31806540" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] castration-resistant prostate cancer. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] recombination repair–related genes studied. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline <i>BRCA</i> mutation. <em>N Engl J Med</em> 2017;377:523-533.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_17_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1706450&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28578601/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407212600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Olaparib+for+metastatic+breast+cancer+in+patients+with+a+germline+BRCA+mutation.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=523-533&amp;doi=10.1056%2FNEJMoa1706450&amp;pmid=28578601" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] described in other monotherapy studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] nausea, as previously noted with the drug. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline <i>BRCA</i>-mutated metastatic pancreatic cancer. <em>N Engl J Med</em> 2019;381:317-327.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1903387&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31157963/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000477993600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Maintenance+olaparib+for+germline+BRCA-mutated+metastatic+pancreatic+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=317-327&amp;doi=10.1056%2FNEJMoa1903387&amp;pmid=31157963" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] nausea, as previously noted with the drug. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. <em>N Engl J Med</em> 2018;379:2495-2505.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa1810858&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30345884/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454351100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Maintenance+olaparib+in+patients+with+newly+diagnosed+advanced+ovarian+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2495-2505&amp;doi=10.1056%2FNEJMoa1810858&amp;pmid=30345884" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] described in other monotherapy studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] nausea, as previously noted with the drug. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. <em>J Clin Oncol</em> 2015;33:244-250.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2014.56.2728" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25366685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000352421400008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Olaparib+monotherapy+in+patients+with+advanced+cancer+and+a+germline+BRCA1%2F2+mutation.&amp;publication_year=2015&amp;journal=J+Clin+Oncol&amp;pages=244-250&amp;doi=10.1200%2FJCO.2014.56.2728&amp;pmid=25366685" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] inhibition in prostate and other cancers. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] castration-resistant prostate cancer. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">O’Connor MJ. Targeting the DNA damage response in cancer. <em>Mol Cell</em> 2015;60:547-560.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molcel.2015.10.040" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26590714/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000368288700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+the+DNA+damage+response+in+cancer.&amp;publication_year=2015&amp;journal=Mol+Cell&amp;pages=547-560&amp;doi=10.1016%2Fj.molcel.2015.10.040&amp;pmid=26590714" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. <em>Biometrics</em> 1979;35:549-556.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2307/2530245" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/497341/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1979HM72500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+multiple+testing+procedure+for+clinical+trials.&amp;publication_year=1979&amp;journal=Biometrics&amp;pages=549-556&amp;doi=10.2307%2F2530245&amp;pmid=497341" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. <em>N Engl J Med</em> 2009;361:123-134.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1911440&amp;key=10.1056%2FNEJMoa0900212&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19553641/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000267748900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibition+of+poly%28ADP-ribose%29+polymerase+in+tumors+from+BRCA+mutation+carriers.&amp;publication_year=2009&amp;journal=N+Engl+J+Med&amp;pages=123-134&amp;doi=10.1056%2FNEJMoa0900212&amp;pmid=19553641" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">de Bono JS, Chowdhury S, Feyerabend S, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥24 weeks in Europe. <em>Eur Urol</em> 2018;74:37-45.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eururo.2017.07.035" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28844372/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436486900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antitumour+activity+and+safety+of+enzalutamide+in+patients+with+metastatic+castration-resistant+prostate+cancer+previously+treated+with+abiraterone+acetate+plus+prednisone+for+%E2%89%A524+weeks+in+Europe.&amp;publication_year=2018&amp;journal=Eur+Urol&amp;pages=37-45&amp;doi=10.1016%2Fj.eururo.2017.07.035&amp;pmid=28844372" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r23-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] evidence to support this approach. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and retrospective studies has varied. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Khalaf D, Annala M, Finch DL, et al. Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): results for 2nd-line therapy. <em>J Clin Oncol</em> 2018;36:5015-5015.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.5015" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000442916002126" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+2+randomized+cross-over+trial+of+abiraterone+%2B+prednisone+%28ABI%2BP%29+vs+enzalutamide+%28ENZ%29+for+patients+%28pts%29+with+metastatic+castration+resistant+prostate+cancer+%28mCPRC%29%3A+results+for+2nd-line+therapy.&amp;publication_year=2018&amp;journal=J+Clin+Oncol&amp;pages=5015-5015&amp;doi=10.1200%2FJCO.2018.36.15_suppl.5015" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Terada N, Maughan BL, Akamatsu S, et al. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. <em>Int J Urol</em> 2017;24:441-448.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/iju.13346" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28455853/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405209900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Exploring+the+optimal+sequence+of+abiraterone+and+enzalutamide+in+patients+with+chemotherapy-na%C3%AFve+castration-resistant+prostate+cancer%3A+the+Kyoto-Baltimore+collaboration.&amp;publication_year=2017&amp;journal=Int+J+Urol&amp;pages=441-448&amp;doi=10.1111%2Fiju.13346&amp;pmid=28455853" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Matsubara N, Yamada Y, Tabata KI, et al. Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. <em>Clin Genitourin Cancer</em> 2018;16:142-148.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.clgc.2017.09.008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29042308/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428941100039" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Abiraterone+followed+by+enzalutamide+versus+enzalutamide+followed+by+abiraterone+in+chemotherapy-naive+patients+with+metastatic+castration-resistant+prostate+cancer.&amp;publication_year=2018&amp;journal=Clin+Genitourin+Cancer&amp;pages=142-148&amp;doi=10.1016%2Fj.clgc.2017.09.008&amp;pmid=29042308" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. <em>Prostate</em> 2017;77:33-40.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pros.23246" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27527643/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000390336000004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparing+sequencing+of+abiraterone+and+enzalutamide+in+men+with+metastatic+castration-resistant+prostate+cancer%3A+a+retrospective+study.&amp;publication_year=2017&amp;journal=Prostate&amp;pages=33-40&amp;doi=10.1002%2Fpros.23246&amp;pmid=27527643" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 26, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2023199" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Olaparib for Metastatic Castration-Resistant Prostate Cancer</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Indianapolis, Indiana</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891387/general-anesthesiologist-with-teaching-opportunities-iu-health-methodist-and-university-hospitals-/?query=fjwp&amp;rid=227332">General Anesthesiologist with Teaching Opportunities (IU Health Methodist &amp; University Hospitals)</a></div></div><div class="nejm-widget_item"><div><span> Colton, California</span></div><div><span>Nephrology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877964/nephrologist-opportunity-loma-linda-ca/?query=fjwp&amp;rid=29477">Nephrologist Opportunity - Loma Linda, CA</a></div></div><div class="nejm-widget_item"><div><span> Saint Louis, Missouri</span></div><div><span>Emergency Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883672/emergency-medicine-physician-with-st-louis-university-hospital-full-time-st-louis-missouri/?query=fjwf&amp;rid=196467">Emergency Medicine Physician with St. Louis University Hospital, Full-Time St. Louis Missouri</a></div></div><div class="nejm-widget_item"><div><span> Winchester, Virginia</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885133/family-medicine-core-faculty-in-shenandoah-valley-family-practice-residency-program/?query=fjwp&amp;rid=246834">Family Medicine Core Faculty in Shenandoah Valley Family Practice Residency Program</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877829/radiologist-breast-100-000-bonus-/?query=fjwf&amp;rid=346908">Radiologist - Breast - $100,000 Bonus!</a></div></div><div class="nejm-widget_item"><div><span> Mooresville, Indiana</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878201/primary-care-physician-in-mooresville-indiana/?query=fjwf&amp;rid=227332">Primary Care Physician in Mooresville, Indiana</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1911440&amp;pubId=41288551&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d62e2bb47e1d0f-GRU">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d62e2bb47e1d0f-GRU"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d62e2bb47e1d0f-GRU"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$212758694$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$212758694$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$212758694$--></div></div><div class="mlt-body"><!--?lit$212758694$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/original-article?query=recirc_Semantic" target="_self"><!--?lit$212758694$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$212758694$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$212758694$-->Jun 03, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043?query=recirc_Semantic" target="_self">Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer</a></div><div class="mlt-article-authors"><!--?lit$212758694$-->N.W. Clarke and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$212758694$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$212758694$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$212758694$-->Dec 10, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2022485?query=recirc_Semantic" target="_self">Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer</a></div><div class="mlt-article-authors"><!--?lit$212758694$-->M. Hussain and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/editorial?query=recirc_Semantic" target="_self"><!--?lit$212758694$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$212758694$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$212758694$-->Aug 23, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDe2200154?query=recirc_Semantic" target="_self">Should We “PROpel” Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?</a></div><div class="mlt-article-authors"><!--?lit$212758694$-->D.J. VanderWeele and M. Hussain</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$212758694$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$212758694$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$212758694$-->Mar 25, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2100225?query=recirc_Semantic" target="_self">Olaparib in Metastatic Castration-Resistant Prostate Cancer</a></div><div class="mlt-article-authors"><!--?lit$212758694$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$212758694$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$212758694$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$212758694$-->Jun 24, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2105215?query=recirc_Semantic" target="_self">Adjuvant Olaparib for Patients with <em>BRCA1</em>- or <em>BRCA2</em>-Mutated Breast Cancer</a></div><div class="mlt-article-authors"><!--?lit$212758694$-->A.N.J. Tutt and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1911440?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1911440" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1911440.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1911440"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Olaparib for Metastatic Castration-Resistant Prostate Cancer</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2008457" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1914919" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f1.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/b3186816-8d37-4708-afa5-bb563ae2327c/assets/images/large/nejmoa1911440_f1.jpg" height="3438" width="2632" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Estimates of Imaging-Based Progression-free Survival and Interim Overall Survival.</div><div class="notes"><div role="doc-footnote">Panel A shows imaging-based progression-free survival, as assessed by blinded independent central review, in patients with at least one alteration in <i>BRCA1</i>, <i>BRCA2</i>, or <i>ATM</i> (cohort A), who received either olaparib or the physician’s choice of enzalutamide or abiraterone (control group); Panel B shows interim overall survival in the same cohort. For patients with censored data in cohort A, the median duration of follow-up for imaging-based progression-free survival was 7.5 months in the olaparib group and 5.4 months in the control group; the median duration of follow-up for overall survival was 12.6 months and 13.2 months, respectively. Panel C shows imaging-based progression-free survival in cohorts A and B (overall population); patients in cohort B had alterations in any of 12 other prespecified genes. For patients with censored data in the overall population, the median duration of follow-up for imaging-based progression-free survival was 7.4 months in the olaparib group and 5.5 months in the control group. Overall, at the time of the analysis of imaging-based progression-free survival by blinded independent central review, 10 patients (4%) in the olaparib group and 8 (6%) in the control group had withdrawn consent, and their data were censored. (For interim overall survival in the overall population, see Fig. S3.)</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f2.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/840a7eee-0ab3-4666-9097-666025b6c990/assets/images/large/nejmoa1911440_f2.jpg" height="1671" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Prespecified Subgroup Analysis of Imaging-Based Progression-free Survival.</div><div class="notes"><div role="doc-footnote">Shown is the subgroup analysis of patients in cohort A (Panel A) and those in the overall population (cohorts A and B) (Panel B). Subgroups in which fewer than five progression events or deaths occurred per group were not included in the analysis. The sizes of the circles are proportional to the number of events. The dashed line indicates the point of no effect (hazard ratio, 1.00). A hazard ratio of less than 1.00 favors olaparib. ECOG denotes Eastern Cooperative Oncology Group, and PSA prostate-specific antigen.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1911440_f3.jpg"><img src="/cms/10.1056/NEJMoa1911440/asset/5ff1be9a-2097-455a-83b5-e1e60cddd366/assets/images/large/nejmoa1911440_f3.jpg" height="2507" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Time to Pain Progression.</div><div class="notes"><div role="doc-footnote">Shown is the probability that patients had no progression of pain during treatment with olaparib or the control drug in cohort A (Panel A) and in cohorts A and B (Panel B). In this analysis, death was not considered as a competing risk. Time to pain progression was based on the worst-pain score (item 3) on the Brief Pain Inventory–Short Form and on opioid use.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events in the Overall Population (Cohorts A and B).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/382/22" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 382 No. 22</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 28, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2008457" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.M. Arons and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 28, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1914919" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">Y.-R. Lee and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 28, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1916038" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.S. Kelly and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1911440%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1911440&amp;pubId=41288551&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1911440%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1911440&amp;pubId=41288551&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id018922846165175145" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d62e2bb47e1d0f-GRU" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d62e2bb47e1d0f-GRU" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d62e2bb47e1d0f-GRU"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d62e2bb47e1d0f-GRU"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d62e2bb47e1d0f-GRU"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d62e2bb47e1d0f-GRU"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d62e2bb47e1d0f-GRU">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d62e2bb47e1d0f-GRU">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d62e2bb47e1d0f-GRU"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d62e2bb47e1d0f-GRU"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d62e2ba88e1d0f',t:'MTc0OTUzMDMxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d62e2ba88e1d0f&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1911440?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><rnh-qmkwjjwtfprv></rnh-qmkwjjwtfprv><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><iframe name="captureIFrame_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-transactionid="0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" id="captureIFrame_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" target="captureIFrame_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="capture_screen"><input id="capture_signIn_js_version_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="js_version"><input id="capture_signIn_transactionId_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" type="hidden" class="capture_transactionId_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="capture_transactionId"><input id="capture_signIn_form_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="form"><input id="capture_signIn_flow_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="flow"><input id="capture_signIn_client_id_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="client_id"><input id="capture_signIn_redirect_uri_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="redirect_uri"><input id="capture_signIn_response_type_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="response_type"><input id="capture_signIn_flow_version_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="flow_version"><input id="capture_signIn_settings_version_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="settings_version"><input id="capture_signIn_locale_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="locale"><input id="capture_signIn_recaptcha_version_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_0zl44dzun0l276jxo2r3vtdyl0mp6zfmf5iskutd" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>